Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.67 |
| ▸ | GSK3B | P49841 | 10/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998502 | 0.87 | GSK3B (0.87) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL11931121 | 0.84 | CDK2 (0.64) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL11931128 | 0.82 | CDK2 (0.64) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13998461 | 0.80 | GSK3B (0.82) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL12953328 | 0.80 | CDK2 (1.00) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13305408 | 0.80 | GSK3B (0.74) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13893732 | 0.77 | GSK3B (0.83) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL12952856 | 0.76 | CDK2 (1.00) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13118479 | 0.75 | GSK3B (1.00) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL14543183 | 0.75 | GSK3B (0.67) | CDK2GSK3BCCNA2CCNA1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-7468372-B2 | Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | CDK2 64/4885GSK3B 334/4885CCNA2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.